Exelixis Grabs Its Share of the Kidney-Cancer Treatment Market

Worries over competition for Exelixis' (NASDAQ: EXEL) Cabometyx appear to be a little overblown after the biotech posted another solid quarter of growth as the drug expands into first-line renal cell carcinoma, the most common form of kidney cancer, and continues to take market share from the second-line players in the space.